FDAFDA recall D-0831-2026 · Sep 2, 2026
Hikma Pharmaceuticals USA INC.: Ramipril Capsules USP recall
Quick answer
- Product
- Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228.
- Brand
- Hikma Pharmaceuticals USA INC.
- Codes, lots and dates
- a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027
- Hazard
- Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
- Distribution
- Nationwide within the United States
- Quantity
- a) 25,970 bottles; b) 2,384 bottles
- Recall date
- Sep 2, 2026
- Agency
- U.S. Food and Drug Administration (FDA) enforcement report
- Recall number
- D-0831-2026
Recall found
Product
Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228.
Reason for recall
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
What to do
FDA enforcement reports don't include consumer instructions. Check the codes below against your packaging. If this is a medicine or device you use, talk to your pharmacist or doctor before you stop or change anything, and contact the company or FDA for what to do with the product.
| Quantity | a) 25,970 bottles; b) 2,384 bottles |
|---|---|
| Codes, lots and dates | a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027 |
| Distribution | Nationwide within the United States |
| Recall date | Sep 2, 2026 |
| Class | Class II |
| Agency ID | D-0831-2026 |
| Official notice | U.S. Food and Drug Administration (FDA) enforcement report |
| Data as of, last checked | Nov 21, 2026, 3:48 PM EST |
Recall details
- FDA classification
- Class II: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
- Status
- Ongoing
- Codes, lots and dates
- a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027
- Quantity
- a) 25,970 bottles; b) 2,384 bottles
- Distribution
- Nationwide within the United States
- Recalling firm
- Hikma Pharmaceuticals USA INC., Columbus, OH
- Voluntary or mandated
- Voluntary: Firm initiated
- Recall started
- 2026-08-24
Source: openFDA enforcement record D-0831-2026 · search recall number D-0831-2026 in FDA's Enforcement Report.
Copied from the agency record without changes. Data as of Nov 21, 2026, 3:48 PM EST. The agency notice is the final word.
FAQ
What was recalled?
Product: Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228. Brand: Hikma Pharmaceuticals USA INC. Codes, lots and dates: a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027
What is the hazard?
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
How do I check if mine is affected?
Codes, lots and dates: a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027
Where was it distributed?
Nationwide within the United States
Related recalls
- Hikma Pharmaceuticals USA INC.: Ciprofloxacin Tablets recall
- Hikma Pharmaceuticals USA INC.: Ciprofloxacin Tablets recall
- Hikma Pharmaceuticals USA INC.: Abirtega (abiraterone acetate) USP recall
- Greenwich: Compounded sterile products
- Breckenridge Pharmaceutical, Inc.: Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg
- React Health dba 3B Medical, Inc.: Bilevel Positive Airway Pressure (BPAP) System
